Celgene — Merger or Acquisition (July 2015)
29 slides from Celgene's merger presentation, Jul 15, 2015
Slide 1: Celgene Announces Acquisition of Receptos
Celgene Announces Acquisition of Receptos July 14, 2015
Slide 2: Agenda
Agenda 2 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celgen
Slide 3: Forward Looking Statements and Adjusted Financial Information
Forward Looking Statements and Adjusted Financial Information Thi s presentatio n contain s forward - lookin g statements , whic h ar e generall y s tatement s tha t ar e not historica l facts . Forward - lookin g s tatement s ca n b e identifie d b y th e word s “ expects, ” “anticipates,” “believe
Slide 4: Additional Information on the Tender Offer
Additional Information on the Tender Offer The tender offer described herein has not yet commenced. The description contained herein is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any shares of Receptos. At the time the tender offer is commenced
Slide 5: Agenda
Agenda 5 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celgen
Slide 6: Our Mission and Vision
Our Mission and Vision Celgene is building a preeminent global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for unmet medical needs in cancer and immune - inflammatory diseases 6
Slide 7: Our Focus: Executing on Five Strategic Imperatives
OUR FOCUS: Executing on Five Strategic Imperatives Operational excellence Capitalizing on strength in Hematology Expanding the Oncology franchise Sustaining innovation and long - term growth Building an Immunology & Inflammation franchise 7
Slide 8: Operational Excellence
Operational Excellence • Exceptional Q2:15 Financial Performance (preliminary) – Total Revenue of approximately $2.28 billion, 22% year - over - year increase – Adjusted EPS of approximately $1.23, including a $0.06 gain on the sale of an equity investment, 37% year - over - year increase • Signific
Slide 9: Sustaining Innovation and Long-Term Growth
Sustaining Innovation and Long - Term Growth • Added Significant Next - generation Growth Drivers – Deals with AstraZeneca, Juno, and Receptos enhance our existing pipeline by adding the potential of 4 product approvals in multiple diseases by 2020 – Accelerated revenue and earnings growth expected
Slide 10: Ozanimod Is a Strong Strategic Fit with Significant Potential
x Leverages existing I&I capabilities and future IBD commercial infrastructure x Neutral to adjusted EPS in 2018; accretive beginning in 2019 x Raising 2020 targets to $ 21B+ in revenue (+$1B) & $13.00+ in adjusted EPS (+$0.50) Financially Compelling Ozanimod Is a Strong Strategic Fit with Significa
Slide 11: Agenda
Agenda 11 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celge
Slide 12: Receptos is a Strong Strategic Fit for Celgene I&I
Receptos is a Strong Strategic Fit for Celgene I&I Disruptive I&I Products • Ozanimod is a potential best - in - class oral S1P receptor modulator in late - stage development presenting a $4B - $6B peak sales opportunity • Ozanimod advancing in Phase III for Ulcerative Colitis and Relapsing Multiple
Slide 13: Combined Robust and Deep I&I Pipeline
Programs and Indications Pre - Clinical Phase I Phase II Phase III Reg. Approval OTEZLA (PDE4 inhibitor) Psoriatic Arthritis Psoriasis Beh ç et Syndrome Ankylosing Spondylitis Atopic Dermatitis Ulcerative colitis GED - 0301 (Smad7 antisense oligo) Crohn’s Disease Ulcerative Colitis (planned) Ozanimo
Slide 14: Phase III Ozanimod Data Expected Beginning in H1:17
Phase III Ozanimod Data Expected Beginning in H1:17 14 • RADIANCE: Phase II / III trial in R elapsing Multiple Sclerosis – Enrollment completed in March 2015 – Data expected in H1:17 • SUNBEAM: Phase III trial in Relapsing Multiple Sclerosis – Enrollment initiated December 2014 – Data expected in H1
Slide 15: Accelerating Momentum in the I&I Portfolio
Accelerating Momentum in the I&I Portfolio Celgene existing Receptos 15 1 Under co - development option with AbbVie Multiple Blockbuster Products Expected in I&I Significant Growth through 2020 and beyond OTEZLA ® PsA / Psor 2014 Ozanimod RMS 2018E Ozanimod UC 2019E GED - 0301 CD 2019E
Slide 16: Celgene I&I Targets Sizable Evolving Markets with Disruptive Oral Therapies
Celgene I&I Targets Sizable Evolving Markets with a Portfolio of Disruptive Oral Therapies 16 Celgene I&I Portfolio Rheumatology Dermatology Gastroenterology / IBD Neuro - Inflammation Therapeutic Area Market Size ($B) 2014E 2020E $27 $34 $11 $17 $9 $15 $20 $27 Total ($B) $67 $93 Targeted Indication
Slide 17: Agenda
Agenda 17 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celge
Slide 18: Ozanimod: Potential Best-in-Class Oral S1PR Modulator
Ozanimod: Potential Best - in - Class Oral S1PR Modulator Transformational Potential in UC, MS and Beyond • Highly selective for S1P1 & S1P5 • Negligible S1P3 activity = less CV tox • PK – delayed C max , T 1/2 , V d • No pro - drug Dose - Attuned Titration Schedule Intrinsic Properties: Product Att
Slide 19: Ozanimod: A Potentially Transformational Profile in UC
Ozanimod: A Potentially Transformational Profile in UC Ozanimod Induction of Remission and Response Mucosal Healing Once - daily Oral Dosing AEs & SAEs Similar to Placebo Rapid Onset of Efficacy 32 - Week Maintenance 19 x Novel oral treatments x Effective treatments to induce clinical response and t
Slide 20: Tremendous Opportunity for Ozanimod to Disrupt the UC Treatment Paradigm
Tremendous Opportunity for Ozanimod to Disrupt the UC Treatment Paradigm Expected Positioning of UC Treatments 1 st line treatment 2 nd line treatment 3rd line treatment Last line treatment 5 - Aminosalicylates Immunosuppressants and Corticosteroids Tysabri ® Ozanimod Remicade ® Humira ® Entyvio ® 4
Slide 21: TOUCHSTONE Trial Results Reveal Transformational Potential in Moderate-to-Severe UC
6.2% 9.3% 8.5% 16.4% 16.5% 17.3% 0% 5% 10% 15% 20% Ozanimod Wk 8 Phase II Humira Wk 8 Phase III Ozanimod Wk 32 Phase II Humira Wk 52 Phase III TOUCHSTONE Trial Results Reveal Transformational Potential for Ozanimod in the Treatment of Moderate - to - Severe UC • Efficacy: – Met primary efficacy and
Slide 22: Ozanimod Addresses Significant Unmet Medical Needs in Relapsing MS
x Therapies that offer improved disease control for relapsing forms of MS x Additional safe and well - tolerated oral therapies x Therapies appropriate for long - term use x Agents that halt and / or reverse disability Unmet Needs in RMS Differentiated Clinical Profile Current profile based on Phase
Slide 23: Orals to Represent ~70% of the $27B MS Market in 2020
Orals to Represent 60 - 70% of the $27B MS Market in 2020 $0 $15 $494 $1,204 $3,029 $5,957 $17,500 $0 $5,000 $10,000 $15,000 $20,000 2009 2010 2011 2012 2013 2014 2020E Ozanimod: Best - in - Class S1P1 Potential for Utilization in First - Line RMS * = Oral treatment Newly diagnosed 1 st line treatme
Slide 24: Cross Trial Comparisons of Select Oral MS Therapies
Ozanimod Phase II Efficacy Comparison to GILENYA ® and TECFIDERA ® 82% 55% 90% 53% 74% 44% 86% 31% 86% 53% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% GD+ Lesion Reduction* ARR Reduction* GILENYA FREEDOMS (0.5mg qd) TECFIDERA DEFINE (240mg bid) TECFIDERA CONFIRM (240mg bid) Ozanimod 0.5mg Phase II *
Slide 25: Agenda
Agenda 25 Bob Hugin, Celgene Chairman & Chief Executive Officer • Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology • Enhancing the I&I Franchise Peter Kellogg, Celgene Executive Vice President & Chief Financial Officer • Transaction Overview Mark Kreston, Celge
Slide 26: Transaction Overview
Acquisition leverages our commercial structure / expertise, further diversifies revenue and enhances long - term growth Transaction Overview 26 Consideration Financing Financial benefits Other • All - cash consideration of $232 per share • Total transaction value of $7.2 billion, net of cash • Sourc
Slide 27: Celgene Announces Acquisition of Receptos
Celgene Announces Acquisition of Receptos July 14, 2015
Slide 28: Reconciliation Tables
A ZA Celgene © Reconciliation Tables
Slide 29: wen soun nba we os uo wed aot pared
wen soun nba we os uo wed aot pared uum RON ue EY “SEY ‘sueunape cu soley poms a peg si pagaruoumbve mG) ‘pany ) “(eany) 2 yoreesey somuogny euaijap pe sxesqy “Qas2om99) do aay ‘uaa uogesvaiuos pst. ‘sea ssa ap say pocunoure 2930 no20 Kew yep (suey) rT ur ‘suowsnboe ose i ( suns jo voneundyy ‘sda, f